Tasquinimod inhibits prostate cancer growth in bone through alterations in the bone microenvironment

No abstract is available for this paper.

• Publication year

  2016

• Venue

  The Prostate

• Publication date

  2016-03-01

• Fields of study

  Biology, Medicine, Environmental Science

• Identifiers
  DOI 10.1002/pros.23133PMID 26660725
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Long-term Safety and Antitumor Activity in the Phase 1-2 Study of Enzalutamide in Pre- and Post-docetaxel Castration-Resistant Prostate Cancer.

  2015cited by this paper
• ResearchTasquinimod ( ABR-215050 ) , a quinoline-3-carboxamide anti-angiogenic agent , modulates the expression of thrombospondin-1 in human prostate tumors

  2015cited by this paper
• HDAC4 integrates PTH and sympathetic signaling in osteoblasts

  2014cited by this paper
• Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial.

  2014cited by this paper
• Tasquinimod Modulates Suppressive Myeloid Cells and Enhances Cancer Immunotherapies in Murine Models

  2014cited by this paper
• The class II histone deacetylase HDAC4 regulates cognitive, metabolic and endocrine functions through its expression in osteoblasts

  2014cited by this paper
• Mechanism of action and clinical activity of tasquinimod in castrate-resistant prostate cancer

  2014cited by this paper
• Tasquinimod Is an Allosteric Modulator of HDAC4 survival signaling within the compromised cancer microenvironment.

  2013cited by this paper
• LOX-mediated collagen crosslinking is responsible for fibrosis-enhanced metastasis.

  2013cited by this paper
• Osteoblasts stimulate the osteogenic and metastatic progression of castration-resistant prostate cancer in a novel model for in vitro and in vivo studies

  2013cited by this paper
• Myeloid-Derived Suppressor Cells Regulate Natural Killer Cell Response to Adenovirus-Mediated Gene Transfer

  2012cited by this paper
• Premetastatic niche: ready for new therapeutic interventions?

  2012cited by this paper
• Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study.

  2012cited by this paper
• Inhibition of metastasis in a castration resistant prostate cancer model by the quinoline‐3‐carboxamide tasquinimod (ABR‐215050)

  2012cited by this paper
• S100A9 Interaction with TLR4 Promotes Tumor Growth

  2012cited by this paper
• The rationale for targeting the LOX family in cancer

  2012cited by this paper
• Tasquinimod prevents the angiogenic rebound induced by fractionated radiation resulting in an enhanced therapeutic response of prostate cancer xenografts

  2012cited by this paper
• Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow.

  2011cited by this paper
• Global cancer statistics

  2011cited by this paper
• Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer.

  2011cited by this paper
• Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999–2006

  2011cited by this paper
• Cadherin-11 increases migration and invasion of prostate cancer cells and enhances their interaction with osteoblasts.

  2010cited by this paper
• HDAC4 Represses Matrix Metalloproteinase-13 Transcription in Osteoblastic Cells, and Parathyroid Hormone Controls This Repression*

  2010cited by this paper
• N-cadherin increases after androgen deprivation and is associated with metastasis in prostate cancer.

  2010cited by this paper
• Molecular mechanisms of the inhibitory effect of lipopolysaccharide (LPS) on osteoblast differentiation.

  2010influential reference
• Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance

  2010cited by this paper
• Lysyl Oxidase (Lox) Gene Deficiency Affects Osteoblastic Phenotype

  2009cited by this paper
• Identification of Human S100A9 as a Novel Target for Treatment of Autoimmune Disease via Binding to Quinoline-3-Carboxamides

  2009cited by this paper
• Tumor‐associated macrophages (TAM) as major players of the cancer‐related inflammation

  2009cited by this paper
• Hematopoietic stem cells do not depend on N-cadherin to regulate their maintenance.

  2009cited by this paper
• Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche.

  2009cited by this paper
• Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer 1

  2009cited by this paper
• Paradoxical Roles of IL-4 in Tumor Immunity

  2009cited by this paper
• Prostate cancer cells modulate osteoblast mineralisation and osteoclast differentiation through Id-1

  2009cited by this paper
• Myeloid-derived suppressor cells as regulators of the immune system

  2009cited by this paper
• Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein

  2008cited by this paper
• Proinflammatory S100 Proteins Regulate the Accumulation of Myeloid-Derived Suppressor Cells1

  2008cited by this paper
• Altered expression of genes regulating angiogenesis in experimental androgen‐independent prostate cancer

  2008cited by this paper
• Cadherin-11 Promotes the Metastasis of Prostate Cancer Cells to Bone

  2008cited by this paper
• The bone marrow niche: habitat to hematopoietic and mesenchymal stem cells, and unwitting host to molecular parasites

  2008cited by this paper
• S100A8/S100A9 and their association with cartilage and bone

  2007cited by this paper
• The RANK/RANKL/OPG triad in cancer-induced bone diseases

  2007cited by this paper
• The quinoline‐3‐carboxamide anti‐angiogenic agent, tasquinimod, enhances the anti‐prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts

  2007cited by this paper
• Identification of ABR‐215050 as lead second generation quinoline‐3‐carboxamide anti‐angiogenic agent for the treatment of prostate cancer

  2006cited by this paper
• Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis

  2006cited by this paper
• G-CSF potently inhibits osteoblast activity and CXCL12 mRNA expression in the bone marrow.

  2005cited by this paper
• Cell-to-cell contact is critical for the survival of hematopoietic progenitor cells on osteoblasts.

  2004cited by this paper
• Osteoblastic cells regulate the haematopoietic stem cell niche

  2003cited by this paper
• Identification of the haematopoietic stem cell niche and control of the niche size

  2003cited by this paper
• Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts.

  2003cited by this paper
• Inflammation and cancer

  2002cited by this paper
• Prostate cancer cells induce osteoblast differentiation through a Cbfa1-dependent pathway.

  2001cited by this paper
• Regulation of Cardiovascular Development and Physiology by Hypoxia‐Inducible Factor 1a

  1999cited by this paper
• Osteomimetic properties of prostate cancer cells: A hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment

  1999cited by this paper
• [Inflammation and cancer].

  1974cited by this paper

• Preclinical efficacy of tasquinimod-based combinations in advanced myeloproliferative neoplasms in blastic phase

  2025cites this paper
• M2 macrophages-derived exosomes regulate osteoclast differentiation by the CSF2/TNF-α axis

  2024cites this paper
• Identification and validation of cancer-associated fibroblast-related subtypes and the prognosis model of biochemical recurrence in prostate cancer based on single-cell and bulk RNA sequencing

  2023cites this paper
• S100A8/S100A9 Promote Progression of Multiple Myeloma via Expansion of Megakaryocytes

  2023cites this paper
• Advancing Treatment of Bone Metastases through Novel Translational Approaches Targeting the Bone Microenvironment

  2022cites this paper
• Costimulatory Effect of Rough Calcium Phosphate Coating and Blood Mononuclear Cells on Adipose-Derived Mesenchymal Stem Cells In Vitro as a Model of In Vivo Tissue Repair

  2020cites this paper
• Visualisation and monitoring of tumour-mediated immune modulation in primary cancer and premetastatic niche establishment using S100A8/A9-specific imaging

  2017cites this paper
• Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH Trial

  2017cites this paper
• Diagnostic, prognostic and predictive value of cell-free miRNAs in prostate cancer: a systematic review

  2016cites this paper
• Radium-223: Insight and Perspectives in Bone-metastatic Castration-resistant Prostate Cancer.

  2016cites this paper
• Cell and Signal Components of the Microenvironment of Bone Metastasis Are Affected by Hypoxia

  2016cites this paper